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Quantitative studies of human urinary excretion of uropontin. Uropon-
tin is the urinary form of osteopontin, an aspartic acid-rich phosphorylated
glycoprotein. Uropontin has been previously shown to be a potent
inhibitor of the nucleation, growth and aggregation of calcium oxalate
crystals and the binding of these crystals to renal epithelial cells. Quanti-
tative data defining the excretion of this protein are necessary to deter-
mine its role in urinary stone formation. In the present studies, we
determined uropontin excretion rates of normal humans. Urine samples
were obtained under conditions of known dietary intake from young adult
human volunteers with no history, radiographic or laboratory evidence of
renal disease. Urinary concentrations of uropontin were measured by a
sensitive ELISA employing an affinity purified polyclonal antiserum to
uropontin. Thirteen normal subjects ingested a constant diet providing 1
gram of calcium, 1 gram of phosphorus, 150 mEq of sodium and 1 gram
of protein per kilogram of body wt per day during an eight day study
period. The relationship of urinary volume to uropontin excretion was
assessed by varying fluid intake on the last four days of the study to change
the mean urine volume/24 hr by . 500 ml. Urine collected in six hour
aliquots for eight days was analyzed for uropontin by ELISA, and for
calcium, and creatinine. Daily uropontin excretion of 13 individual
subjects was 3805 6 1805 mg/24 hr (mean 6 1 SD). The mean urinary levels
(1.9 mg/ml) detected in the present study are sufficient for inhibition of
crystallization; our previous studies have demonstrated that the nucle-
ation, growth and aggregation of calcium oxalate crystals and their binding
to renal cells in vitro are inhibited by this concentration of purified
uropontin. In contrast to the regular pattern of diurnal variation of
calcium excretion seen in most subjects, uropontin excretion showed no
regularity of diurnal variation and was not directly related to either
calcium or creatinine excretion or changes in urinary volume. However,
uropontin concentration varied inversely with urine volume (P # 0.001),
so that the highest uropontin concentrations occurred when urine volume
was the lowest. We conclude that the physiologic characteristic of an
inverse relationship of uropontin concentration to urine volume favors
protection from urinary crystallization of calcium oxalate by uropontin.
Our quantitative definition of urinary uropontin excretion of normal
adults provides the basis for the evaluation of uropontin excretion by
individuals who have formed urinary stones.
The majority of urinary stones are composed of calcium salts
and the predominant constituent of most urinary calculi is calcium
oxalate [1, 2]. Urine excreted by normal individuals, as well as
stone-formers, is often supersaturated with respect to calcium
oxalate. However, the complex process of stone formation is
inhibited by substances in urine that raise the concentrations of
calcium and oxalate that are required for new crystal formation,
growth and aggregation and inhibit adhesion of crystals to renal
epithelial cells [2–5]. Although small molecules, such as magne-
sium, pyrophosphate and citrate have been shown to be inhibitory
[6], the majority of the inhibition of calcium oxalate crystallization
in urine appears to be provided by its protein constituents [2, 7].
A variety of inhibitory activities have been reported for several
human urinary proteins, including nephrocalcin, Tamm-Horsfall
protein and uropontin [5, 7–10]. At present, the relative contri-
butions of these proteins to the inhibition of stone formation is
not known.
The urinary form of osteopontin (uropontin) was initially
isolated by monoclonal antibody immunoaffinity purification from
normal human urine as an inhibitor of calcium oxalate crystal
growth [10]. Subsequently, this aspartic acid-rich phosphorylated
glycoprotein was shown to also be a potent inhibitor of calcium
oxalate nucleation, aggregation and binding to renal epithelial
cells [5, 11]. Although the immunologic characteristics of os-
teopontin isolated from different tissues are not identical [12], the
structural basis of these differences has not been defined and the
terms, urinary osteopontin and its contraction, uropontin are used
interchangeably. Studies of osteopontin secreted by mouse renal
cells in culture have also demonstrated potent inhibition of
calcium oxalate crystallization [13, 14]. Furthermore, uropontin is
incorporated into calcium oxalate monohydrate stones [15–17].
Renal production of osteopontin has been well established by in
situ hybridization, light and ultrastructural immunochemical lo-
calization in mouse, rat and human kidneys [18–21]. Osteopontin
has been ultrastructurally localized to the cells of the descending
thin limb of Henle’s loop and papillary surface epithelium of
normal rat and mouse kidneys. Localization in distal nephron
segments (thick ascending limb and distal convoluted tubule) has
been less consistently detected. The more focal distribution within
the distal nephron may reflect mild subclinical tubular injury,
since a marked up-regulation of osteopontin expression in the
distal nephron is induced by several forms of renal injury [sum-
marized in 20]. With respect to calcium oxalate stone disease, it is
noteworthy that osteopontin expression was markedly increased
in distal nephrons of rats given ethylene glycol to induce hyper-
oxaluria [22] and that osteopontin production of cultured primate
renal epithelial cells is stimulated by exposure to calcium oxalate
crystals [23].
Since quantitative information concerning normal rates of
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uropontin excretion and effects of factors that influence its
excretion is required to precisely define the role of uropontin in
stone formation, a quantitative immunoassay for urinary uropon-
tin was developed in our laboratory. In the present studies, this
enzyme linked immunoassay (ELISA) employing affinity-purified
polyclonal antibodies to uropontin was used to characterize
normal urinary uropontin excretion. Urine samples from each of
a group of normal adults were obtained during an eight day period
under conditions of known dietary intake. The diurnal pattern of
uropontin excretion was determined and relationships of uropon-
tin excretion to urinary volume, calcium and creatinine excretion
were analyzed. These studies provide the first quantitative data
concerning normal patterns of urinary excretion of uropontin.
They show that the quantities of uropontin excreted are sufficient
to make an important contribution to the inhibition of calcium
oxalate crystallization in normal urine.
METHODS
Subject selection
Normal adult volunteers (aged 19 to 35 years old) were
admitted to the General Clinical Research Center of the Hospital
of the University of Pennsylvania. These individuals were free of
a history of kidney stone disease or radiographic evidence of
kidney stone disease. Serum calcium and creatinine and urinary
calcium and creatinine excretion per 24 hours were measured
prior to entry; individuals with abnormal values (. 300 mg
calcium per 24 hr for men and . 250 mg calcium per 24 hr for
women; . 4 mg calcium per kilogram body wt per 24 hr) were
excluded from this study.
The subjects ingested a defined diet containing 1 gram of
calcium, 1 gram of phosphate, 150 mEq of sodium and 1 gram of
protein per kilogram of body wt per day throughout the study
period. After a three day period of equilibration to this diet, a
series of 32 consecutive six-hour collections of urine were ob-
tained from each subject during a period of eight days. In order to
evaluate the relationship of urinary volume to uropontin excre-
tion, oral water intake on the last four days of the study was either
increased or decreased on average by more than 500 ml/day in 11
of 13 subjects (. 1000 ml change in 9 subjects) from that ingested
during the first four days. The total volume and concentrations of
calcium, creatinine, sodium, potassium, phosphate and uropontin
were determined using aliquots from each of the six hour collec-
tions. Sodium azide (0.02%) and two protease inhibitors, Phenyl
methyl sulfonyl fluoride (PMSF; 0.5 mM; Sigma) and N-ethyl
maleimide (NEM; 1.0 mM; Sigma) were added to urine samples
that were kept at 4°C prior to assay for uropontin. The majority of
samples were assayed within three weeks after collection and
stability during more prolonged storage for this set of samples was
demonstrated by repeating assays after longer intervals including
those exceeding a year after initial assay.
Immunoassay
Our previously described enzyme-linked immunoassay
(ELISA) for uropontin [10] was modified as follows to more
optimally detect uropontin in urine samples. Protein solutions
diluted with a 0.5 M ethylenediaminetetraacetic acid (EDTA)
buffer, pH 9.3 were used to directly coat 96-well polyvinyl chloride
microtiter plates (Dynatech) for 15 hours at 4°C. The washing
buffer contained 0.01 M Tris, 0.154 M NaCl, 5 mM CaCl2, 0.05%
Tween 20 at pH 7.6. The blocking buffer contained 8 mg/ml of
bovine serum albumin (BSA) in the washing buffer. All immuno-
assays for uropontin were performed using a series of twofold
dilutions of a single preparation of affinity purified uropontin on
each plate as standards. Concentrations of uropontin in samples
were calculated using the curve derived from the optical densities
of the standards run on the same plate. Each sample was
measured in triplicate at four dilutions with the initial dilution of
urine being 1:80 or 1:100. If the mean optical densities of at least
two dilutions of a urine did not fall within the linear portion of the
standard curve for that plate, the assay for that sample was
repeated using an appropriate series of dilutions. The primary
antibody was an affinity-purified polyclonal rabbit anti-uropontin
prepared in our laboratory as described below and the secondary
antibody was an affinity purified peroxidase conjugated goat
anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA,
USA).
Preparation of monospecific polyclonal antibodies to uropontin
Polyclonal antibodies to uropontin was prepared by immunizing
rabbits with uropontin isolated by immunoaffinity purification
using monoclonal antibody ZH2 beads as previously described
[10, 18]. After multiple exposures of this antiserum to a urinary
protein fraction that had been coupled to Sepharose 4B® beads,
a monospecific anti-uropontin antiserum (pUP-1) was obtained.
The immobilized urinary protein fraction used for the affinity
removal of antibodies with undesired specificities was a DEAE-
cellulose batch eluate [7] that had been previously depleted of
uropontin by exposure to ZH2 beads. After affinity purification,
pUP-1 did not react with any other urinary proteins by ELISA or
by Western blotting. All immunoassays were performed using
dilutions of the same preparation of affinity purified uropontin on
each plate as standards.
Levels of sodium, potassium, phosphate, calcium and creatinine
were determined by standard techniques [24].
All data were analyzed by using paired or unpaired t-tests and
linear correlation using the Statworks® program for the Macin-
tosh computer.
RESULTS
Immunoassay
The sensitivity of detection provided by several types of ELISAs
employing polyclonal and/or monoclonal antibodies to uropontin
was evaluated prior to adopting the assay for uropontin used in
the present studies. Since calcium influences the conformation of
osteopontin [12], EDTA was added to some coating buffers in
preliminary studies to determine if the absence of calcium influ-
enced uropontin coating. Concentrations of uropontin between 5
and 50 nanograms per ml were detected by the affinity purified
antiserum, pUP-1 in an ELISA employing microtiter plates
directly coated with samples that had been diluted in an EDTA
buffer. Direct comparisons showed that the ELISA using this
polyclonal antiserum was roughly 10 times more sensitive than a
comparable procedure employing monoclonal antibody ZH2.
Undiluted urine inhibited detection of uropontin and this protein
was less reliably detected if solutions containing low or no EDTA
were used to coat microtiter plates. EDTA concentrations . 0.1
M allowed better detection from solutions that contained other
proteins; in the studies reported here, dilutions in 0.5 M EDTA,
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pH 9.3 were used for all samples. The assay was validated in
recovery studies in which purified uropontin was added to diluted
urine samples. The recovery of uropontin added to 23 samples
that had been sufficiently diluted ($ 1:100) was 77.4 6 31.1%.
Significantly less uropontin (45.8 6 30.8%) was recovered after an
initial tenfold dilution of urine samples (P 5 0.003). The mean
coefficient of variation for multiple determinations performed on
81 individual urine samples was 24.0%. Although the coefficient
of variation was not linearly related to the concentration of
uropontin in individual samples, variability was greatest at the
lowest concentrations. More than 2/3 of the samples with uropon-
tin concentrations of , 1.0 mg/ml had a coefficient of variation .
50%, whereas only a sixth of the samples with . 1.0 mg/ml showed
this extent of variability. Protein concentrations of the uropontin
standard determined by the Lowry method and by quantitative
aminoacid analysis after alkaline hydrolysis showed close agree-
ment. By comparison, analysis using Coomassie Blue dye binding
assay greatly underestimated uropontin concentrations.
Rates of uropontin excretion
The mean daily excretion of uropontin over the eight day
period of collections for the group of 13 subjects was 3805 6 1805
mg/24 hr. Values for individual subjects (mean 6 SD) ranged on
individual days from 274 to 11,140 mg (Fig. 1). When factored for
body size, the mean rate of uropontin excretion was 57.7 6 26.9
mg/kg/24 hr. The rate of uropontin excretion by the 9 male
subjects (62.0 6 28.0 mg/kg/24 hr) was not significantly higher than
that of the female subjects (49.2 6 9.9 mg/kg/24 hr; P 5 0.397).
Analysis of individual collection periods showed that the high-
est concentrations of uropontin were detected in the six hour
collections with the lowest volumes (Fig. 2) and demonstrated that
an inverse relationship between urine volume and uropontin
concentration generally prevailed (r value 5 0.532). To explore
this relationship, the average oral water intake of 11 subjects
during the last four days of the study was changed by more than
500 ml/day from that during the first four days. Ten of these
subjects showed a mean change in urinary volume/24 hours that
exceeded 500 ml. The uropontin excretion of 4175 6 1715 mg/24
hr during the four days with lower urine volumes was not
significantly greater than the excretion of 3680 6 2418 mg/24 hr
during the four days that these 10 subjects had higher urine
volumes (P . 0.1 by paired t-test). The mean urinary volume in
the 20 periods of four days for these 10 subjects was 1000 to 2000
ml/24 hr in nine periods, 2000 to 3000 ml in six periods, 3000 to
3600 ml in four periods, and 940 ml in one period. The mean urine
volumes for the six periods of four days of the other three subjects
ranged from 974 to 1602 ml. Further analysis of the relationship of
uropontin excretion to urinary volume demonstrated no signifi-
cant differences based on the volume of urine in the six hour
collections. For example, the mean uropontin excretion in collec-
tions containing more than 750 ml was larger than the mean
excretion in collections with a smaller volume in four of the
subjects and was smaller in six subjects. The overall rate of
uropontin excretion in collections , 750 ml was 1024 6 493 mg/6
hr, and in collections . 750 ml was 846 6 644 mg/6 hr. Further-
more, analysis of individuals showed that mean uropontin excre-
tion in collections . 750 ml/6 hr was not significantly greater than
mean level in the collections , 750 ml/6 hr of the same subject
(N 5 10, P 5 0.112 by paired t-test).
Overall, the mean urinary volume of the 13 subjects was 1988 6
490 ml/day. Thus, the mean concentration of uropontin was 1.914
mg/ml (57 nmol/liter based on the peptide molecular weight of
;33,000).
The majority of subjects showed a regular pattern of diurnal
variation in calcium excretion (Fig. 3). In the seven subjects with
an established rhythm, the lowest calcium excretion occurred
during the first quadrant of the day (between 12 midnight and
6 a.m.) in 55 of the combined total of 56 days that they were
studied. By contrast, the rate of uropontin excretion of these
individuals showed less variability during the periods of the day
and no regular diurnal variation (Fig. 3). For the entire group, the
rate ranged from 876 6 489 mg/6 hr in the second quadrant to
1027 6 754 mg/6 hr in the third quadrant. Thus, the highest ratio
Fig. 1. Mean daily excretion of uropontin by 13 normal adult subjects
during a period of eight days (V, mean 6 1 SD); v mean daily excretion
by the group.
Fig. 2. Comparison of the uropontin concentration to the urinary volume
in the six hour collections from each of the 13 normal subjects shown in
Figure 1. The correlation coefficient for these 416 samples is 0.532 (P ,
0.001).
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of uropontin to calcium regularly occurred in the quadrant with
the lowest calcium excretion. Overall, no significant relationship
between uropontin and calcium excretion was seen in either the
six hour collections (Fig. 4) or in excretion per 24 hours with the
regression line, y 5 33.7 1 11.00x for the 104 total daily
collections having an r value of only 0.2. Comparison of the rates
of urinary uropontin excretion to creatinine excretion per 24
hours also showed no significant relationship. The r values for the
linear regression line of 24 hour collections and six hour values
were 0.2 and 0.3, respectively. The mean creatinine excretion for
the 13 subjects was 19.9 mg of creatinine per kilogram body wt per
24 hours. The rate of creatinine excretion was highly reproducible
with the average SEM for the 24 hour collections of individual
subjects being 4.2% (range from 0.96 to 13.1%) of the mean
creatinine excretion for that subject. There was no significant
relationship in the rate of uropontin excretion to the excretion of
sodium, potassium or phosphate.
DISCUSSION
These studies demonstrate that the mean concentration of
uropontin (1.914 mg/ml, or 57 nM) that prevails in normal adult
human urine exceeds levels that will substantially influence several
aspects of calcium oxalate crystallization in vitro. A significant
inverse relationship between uropontin concentration and urinary
volumes was shown (Fig. 2) with high concentrations of uropontin
being present when urinary volumes were low and contained
higher concentrations of mineral constituents.
The relationship of uropontin excretion to that of calcium was
examined in detail, since hypercalciuria is a well known factor
increasing the risk of stone formation. Since calcium excretion
shows a diurnal pattern of variation, urine samples were collected
at six hourly intervals. Whereas the majority of subjects showed a
diurnal pattern of calcium excretion, there was no regular pattern
of diurnal variation of uropontin excretion (Fig. 3). Thus, the
highest ratios of uropontin to calcium were regularly observed
between midnight and 6 a.m., when the rate of calcium excretion
was lowest. The uropontin excretion was not significantly related
to calcium excretion in six hour collections (Fig. 4) or per 24
hours.
The concentrations of uropontin in normal urine over a period
of eight days demonstrated in the present study exceeded the
levels that substantially decrease calcium oxalate crystal growth
and aggregation [11] and the binding of calcium oxalate crystals to
renal epithelial cells [5]. By contrast, the 50% inhibition of
calcium oxalate monohydrate (COM) nucleation using a seeded
nucleation assay occurred at a concentration of uropontin (200
nM) that is roughly tenfold higher than the concentrations re-
quired for equivalent inhibition of crystal growth, aggregation or
adherence to renal epithelial cells [5, 11]. These studies using a
seeded nucleation assay suggest only a modest contribution of
uropontin to nucleation inhibition. However, studies using an
unseeded nucleation assay showed inhibition of nucleation at
concentrations of mouse osteopontin as low as ;10 nM [14].
These latter studies indicate a much greater capacity for inhibition
of nucleation.
In summary, the levels of uropontin prevailing in normal urine
are sufficient to make a considerable contribution to the inhibition
of calcium oxalate crystallization and thereby to be protective
against the most common cause of urinary stone formation.
Definition of the relative contributions of uropontin and other
urinary protein inhibitors of crystallization and risk factors such as
Fig. 3. Excretion of calcium (F) and uropontin
(E) in the series of 32 consecutive urine
samples from one of the subjects. A regular
pattern of diurnal variation is shown in which
the lowest rate of calcium excretion is present
during the six hour period between 12 midnight
and 6 a.m. in each of the eight days of study.
Fig. 4. Comparison of the rates of uropontin excretion to calcium
excretion per six hours in 416 urine collections showed no significant
relationship. The regression line, y 5 12.85 1 3.01x had an r value of 0.1.
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high urine calcium and/or oxalate and low urine citrate, their
potential interactions and their precise roles in urinary stone
formation provide important goals for future studies.
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APPENDIX
Abbreviations used in this study are: ELISA, enzyme linked immuno-
assay; PMSF, phenyl methyl sulfonyl fluoride; NEM, N-ethyl maleimide;
EDTA, ethylenediaminetetraacetic acid; BSA, bovine serum albumin;
pUP-1, monospecific anti-uropontin antiserum; COM, calcium oxalate
monohydrate.
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